BeOne director sells reported direct stake

Posted by Patrick Bannon on Oct 2nd, 2026

What happened

BeOne Medicines Ltd. (NASDAQ: ONC) director Xiaodong Wang sold 31,028 American Depositary Shares on 2026-09-28 for about $11.32 million. The filing says the shares traded from $356.97 to $367.23 per share, and it splits the sale into multiple transactions.

After the sale, Wang held 0 shares. The form says the trades were made under a Rule 10b5-1 trading plan adopted on June 9, 2026. The filing was dated 2026-09-30.

Key numbers

Metric	Latest	Source
Shares sold	31,028 shares	SEC Form 4
Sale value	about $11.32 million	SEC Form 4
Price range	$356.97 to $367.23 per share	SEC Form 4
Shares held after sale	0 shares	SEC Form 4

Read more: BeOne Medicines (ONC) stock analysis and investment case

Why it matters

For investors, this is an ownership update, not an operating update. OptimistFi's case is that BeOne Medicines converts rapid oncology product launches and global commercialization into very high gross margins and, at scale, recurring operating profits and free cash flow.

This filing does not test that business path directly. It does show that Wang fully sold the reported direct position covered here, which matters for anyone tracking insider ownership.

The sale matched the prior reported direct holding exactly. The reported direct stake went from 31,028 shares to 0 shares in one filing.

The 31,028 shares were about 100.0% of the holding before the trade. The sale price range was $356.97 to $367.23 per share, which puts the total value at about $11.32 million.

The plan date is the main caveat because the form gives an earlier adoption date. That makes the sale harder to read as a fresh view on the company.

This filing is the only change that directly affects the ownership map. It gives a clean reset of that direct holding, but it does not change the operating case.

Browse: stock research on every company OptimistFi covers

What's next

The next quarterly report is the next scheduled evidence point for whether BeOne is still turning launches and commercialization into operating profit and free cash flow.

A report that confirms that path would strengthen the case. A report that does not would weaken it.

Until then, this Form 4 is the baseline for Wang's direct ownership after the sale. It also marks 2026-09-30 as the filing date for this update. A new filing would be needed to change that baseline.